123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1688-1693

  Lorberboym, Mordechai ^a,b   Djaldetti, Ruth ^b,c   Melamed, Eldad ^b,c   Sadeh, Menahem ^a,b   Lampl, Yair ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

123I labeled N (3 fluoropropyl) 2 carbomethoxy 3 (4 iodophenyl)nortropane; Dopamine transporters; Parkinson's disease; SPECT; Vascular parkinsonism

Indexed keywords

IODINE 123; LEVODOPA; N (3 FLUOROPROPYL) 2BETA CARBOMETHOXY 3 BETA (4 IODOPHENYL)NORTROPANE I 123; NORTROPANE DERIVATIVE; UNCLASSIFIED DRUG; (12 CYANO 12,13 DIHYDRO 11H CYCLOPENTADIPYRIDO(B 3,2 H, 2',3' J)PHENAZINE 12 CARBOXYLIC ACID METHYL ESTER)BIS(1,10 PHENANTHROLINE)RUTHENIUM(II); (12-CYANO-12,13-DIHYDRO-11H-CYCLOPENTADIPYRIDO(B-3,2-H, 2',3'-J)PHENAZINE-12-CARBOXYLIC ACID METHYL ESTER)BIS(1,10-PHENANTHROLINE)RUTHENIUM(II); ANTIPARKINSON AGENT; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; FEMALE; HEART INFARCTION; HUMAN; MALE; PARKINSONISM; PATIENT ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DRUG EFFECT; METABOLISM; METHODOLOGY; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CEREBROVASCULAR DISORDERS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; ORGANOMETALLIC COMPOUNDS; PARKINSON DISEASE, SECONDARY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 13944254222     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Foltynie T, Barker R, Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology. 2002;21:1-7.
2. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117:859-876.
3. Reider-Groswasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lacunar infarcts of the basal ganglia. Eur Neurol. 1995;35:46-49.
4. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249-260.
5. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. Basal ganglia lacunes and parkinsonism. Neuroepidemiology. 1994;13:108-112.
6. Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology. 1990;40:897-900.
7. Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC. Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord. 1995;10:450-454.
8. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology. 1984;34:1516-1518.
9. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982;32:871-876.
10. Bonucelli U. The elusive vascular parkinsonism [abstract]. Neurology. 1995;45(suppl 4):A339.
11. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683-1689.
12. Chang CM, Yu YL, Ng HK, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol Scand. 1992;86:588-592.
13. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med. 1997;38:1-6.
14. 123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
15. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
16. 123I]Beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002;17:518-523.
17. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:98-102.
18. Critchley M. Arteriosclerotic parkinsonism. Brain. 1929;52:23-83.
19. Zijlmans JC, Thijssen HO, Vogels OJ, et al. MRI in patients with suspected vascular parkinsonism. Neurology. 1995;45:2183-2188.
20. Parkes JD, Marsden CD, Rees JE, et al. Parkinson's disease, cerebral arteriosclerosis, and senile dementia: clinical features and response to levodopa. Q J Med. 1974;43:49-61.
21. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 2001;104:63-67.
22. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism: a clinicopathologic study. Stroke. 1997;28:965-969.
23. 123I]-FP-CIT study group. Mov Disord. 2000;15:503-510.
24. 123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse. 2001;39:101-108.
25. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease: a postmortem study. Acta Neuropathol. 2003;105:415-419.
26. van Zagten M, Lodder J, Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord. 1998;13:89-95.
27. Tohgi H, Takahashi S, Abe T, Utsugisawa K. Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Eur Neurol. 2001;46:1-10.
28. 123I]beta- CIT: binding kinetics in the human brain. J Neural Transm Gen Sect. 1993;94:137-146.
29. 18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-615.
30. 99mTc-TRODAT-1. J Nucl Med. 2001;42:408-413.
31. Takasawa M, Hashikawa K, Ohtsuki T, et al. Transient crossed cerebellar diaschisis following thalamic hemorrhage. J Neuroimaging. 2001;11:438-440.
32. Gonzalez-Aguado E, Marti-Fabregas J, Marti-Vilalta JL. The phenomenon of diaschisis in cerebral vascular disease. Rev Neurol. 2000;30:941-945.